Stocks / Healthcare

Rigel Pharmaceuticals Inc

RIGL Stock Report
Current Price
XXXX
Analyst Target Price
$38.33
Market Cap
XXXX
Updated
September 11, 2025
Analysts
6

Rigel Pharmaceuticals Inc Stock Overview

Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, … More details ➜
1 Year Price Range
Low $13.37 Current High $43.72
PinkLion Scores

Fundamentals Summary

P/E Ratio
6.97x
P/S Ratio
2.53x
Net Income
Revenue
Market Cap

Net Income & Revenue

Last Reported Earnings
June 30, 2025
Earnings per share (EPS) $5.43
Gross Margin 82.79%
Net Profit Margin 36.51%
Debt/Equity Ratio 38.96%

Dividends

Current Dividend Yield
-
Payout Ratio
-
Forward Dividend Yield
-

Price History

Track historical stock performance, price trends, and volatility for RIGL to see how the stock has performed over time.
YTD
1 Year
5 Years
All

Valuation Summary

We estimate a fair price for RIGL by projecting its future cash flows and discounting them back to today with a XXXXX model.

About the Company

IPO Date
November 29, 2000
Employees
162
Sector
Healthcare
Industry
Biotechnology
Country
USA
Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. In addition, the company has product candidates in clinical development with partners BerGenBio ASA, Eli Lilly and Company, and Daiichi Sankyo. It has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of Olutasidenib in AML and other hematologic cancers with IDH1mutations, as well as with collaborative network for neuro-oncology clinical trials to evaluate Olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.